Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Gallbladder Neoplasms 1

Interventions

Gemcitabine 60Cisplatin 38Oxaliplatin 30Capecitabine 28Fluorouracil 21Leucovorin 19pembrolizumab 11Irinotecan 11durvalumab 9130-nm albumin-bound paclitaxel 9Erlotinib Hydrochloride 8Trastuzumab 7Bevacizumab 7Platinum 6Magnetic Resonance Spectroscopy 6Albumin-Bound Paclitaxel 61,2-diaminocyclohexaneplatinum II citrate 6Taxes 5Specimen Handling 5Sorafenib 5Radiotherapy 5Carboplatin 5Docetaxel 4Biopsy 4trifluridine tipiracil drug combination 3dehydroftorafur 3atezolizumab 3Paclitaxel 3Lapatinib 3Interleukin-12 Subunit p35 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Gallbladder Neoplasms × Mutation × Clear all
NCT03772132 2018-12-11

Chemothetapy FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

Shanghai Jiao Tong University School of Medicine

Phase 2 Unknown
100 enrolled
Gastrointestinal

Gallbladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡